Ipamorelin.
Selective ghrelin-receptor agonist with minimal cortisol or prolactin elevation.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About Ipamorelin.
Ipamorelin is a pentapeptide growth-hormone-releasing peptide (GHRP). It is one of the cleanest molecules in its class: it produces a strong, dose-dependent GH pulse without the cortisol, prolactin or aldosterone elevations seen with earlier GHRPs such as GHRP-6 or hexarelin.
It is most commonly prescribed in combination with a GHRH analogue (CJC-1295, sermorelin, tesamorelin) because the two mechanisms are synergistic: GHRH triggers the pituitary to release GH, while ipamorelin amplifies the size of that pulse.
Ipamorelin is a selective agonist of the ghrelin / GHS-R1a receptor on pituitary somatotrophs. Receptor activation triggers a GH pulse mediated by calcium influx and protein kinase C signalling. Its selectivity for GHS-R1a — with negligible activity on receptors that regulate cortisol and prolactin — accounts for its clean side-effect profile.
Subcutaneous injection, 1–2 administrations per day per physician prescription. Typically 200–300 mcg per dose. When stacked with a GHRH analogue, the two are administered together.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- 01Raun K, et al. — Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol · 1998 · doi: 10.1530/eje.0.1390552
- INN / Name
- Ipamorelin
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 5mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.
Within Growth Hormone.
- Cat. 03
Sermorelin
GHRH analogue that prompts the pituitary to release endogenous growth hormone in physiological pulses.
€50.00 - Cat. 03
GHRP-6
First-generation GH-releasing hexapeptide with appetite-stimulating side effect.
€50.00 - Cat. 03
CJC-1295
GHRH analogue — DAC variant gives sustained release, NO-DAC mimics native pulsatility.
€80.00